CDMO Services
We specialize in cutting-edge biologics development to help our partners bring life-saving therapies to patients faster and more efficiently. Our expertise spans antibody drug conjugates (ADCs) and bioconjugate development, bioprocess development, analytical and formulation development services.
- Overview
- Facility
- Bioprocess Development
- Analytical & Formulation Development
- Manufacturing
- Analytical Services
Why Choose Xcellon?
Xcellon brings advanced bioconjugation expertise to be your one-stop US partner from discovery to the clinic.
2 State-of-the-Art US-Based Facilities
Xcellon has two robust facilities in Maryand: a 7,000+ sq ft campus in Rockville and a larger 40,000 sq ft space in Beltsville.
Seamless Processes
We provide upstream, downstream, and conjugation manufacturing with seamless tech-transfer—made possible by our internal technology platforms that allow for single-use, high-potency capable operations.
Decades of Industry Experience
Our team has collectively filed 20+ INDs, has 40+ years of experience in both biologics and bioconjugates, and boasts 30+ years in GMP manufacturing.
Site Safety
Our facilities prioritize safety from hazardous substance exposure with a Target Occupational Exposure Limit (OEL) of 10ng/m³.
Your One-Stop ADC CDMO Partner
Our integrated discovery, development, and manufacturing teams streamline your ADC’s path from target to clinic—on one technology stack, with one agile US partner.
Our Facilities
Both sites are US-based, keeping your program, your material, and your team in the same country and the same working day.
- >5,000 sq ft cleanroom space
- >10,000 sq ft development & analytical lab space
- 2x 1000 L bioreactor capacity
- Segregated bioconjugation suite
- GMP QC lab & warehouse
- cGMP clinical supply
Safer, More-Potent Antibody Therapeutics
Our site-specific conjugation platform delivers ADCs with enhanced stability, more precise DAR control, and improved clinical predictability compared to traditional conjugation methods, enabling more effective and targeted treatments for patients.
Our Offerings
Simultaneous Development
Xcellon runs antibody and conjugate development at once. Because cell line development, bioprocess development, and bioconjugation share a building and a technology stack, conjugate work starts on early antibody material — no transfer package, no handoff, no waiting.
Our Capabilities
Modalities
- Topoisomarase Inhibitors
- Microtubule Inhibitors
- DNA Damaging Payloads
- Dual Linker Payloads
- PROTACs and Protein Degraders
- Immunoregulatory Payloads
- Oligo (ASO, PMO, RNAi)
- DOTA/DOPA cages
- Fluorescent Probes
Our Platform
- Lysine
- Cysteine (stochastic/engineered)
- Glycan Site-Specific Conjugation
- Enzyme-Catalyzed Reactions
- Transglutaminase (MTGase)
- Transglycaolysylation
- Glycoenginnering
- Sartase-tag/enzyme
- Non-Natural Amino Acid
Partner
With Us
Partner With Us
Xcellon Biologics is backed by successful biotech entrepreneurs and professionals from top pharmaceutical and CDMO companies including Lonza, Abzena, Amgen, MedImmune, AstraZeneca, BioNTech, Seattle Genetics, and Immunomedics.
We collaborate with leading innovators and global partners to accelerate biopharmaceutical breakthroughs while maintaining the highest quality and regulatory standards.
